GT Biopharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Michael Breen
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 36.5% |
| CEO tenure | 2.8yrs |
| CEO ownership | 1.3% |
| Management average tenure | no data |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate
Jan 06
GT Biopharma files for $150M mixed shelf offering
Oct 13We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully
Sep 21GT Biopharma GAAP EPS of -$0.10 beats by $0.07
Aug 11Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation
Jun 08Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth
Nov 24Getting To Know GT Biopharma
Jun 06GT Biopharma names Gregory Berk Chief Medical Officer
Apr 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$12m |
| Jun 30 2024 | n/a | n/a | -US$11m |
| Mar 31 2024 | n/a | n/a | -US$10m |
| Dec 31 2023 | US$2m | US$556k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$15m |
| Mar 31 2023 | n/a | n/a | -US$16m |
| Dec 31 2022 | US$2m | US$493k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$33m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$3m | US$63k | -US$58m |
Compensation vs Market: Michael's total compensation ($USD1.53M) is above average for companies of similar size in the US market ($USD645.47K).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
CEO
Michael Breen (61 yo)
2.8yrs
Tenure
US$1,525,834
Compensation
Mr. Michael Martin Breen, LL B serves as Interim Chief Executive Officer at GT Biopharma, Inc. since March 02, 2022. Mr. Breen serves as an Executive Chairman at GT Biopharma, Inc. since November 08, 2021...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Executive Chairman | 4yrs | US$1.53m | 1.28% $ 85.6k | |
| Independent Director | 1.7yrs | US$218.33k | 0% $ 0 | |
| Independent Director | 4yrs | US$586.00k | 0% $ 0 | |
| Independent Vice Chairman | 4.2yrs | US$586.00k | 0.53% $ 35.3k |
4.0yrs
Average Tenure
74.5yo
Average Age
Experienced Board: GTBP's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 02:41 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GT Biopharma, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Walsh | B. Riley Securities, Inc. |
| Charles Butler | Roth MKM |
| Jonathan Aschoff | Roth MKM |